Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Q2 FY2025 Earnings Presentation
39 slides from Jubilant Ingrevia's earnings presentation, Oct 22, 2024
Slide 1: Cover letter to stock exchanges: Investors Presentation
October 22, 2024 BSE Limited National Stock Exchange of India Limited Floor 25, P. J. Towers Exchange Plaza Dalal Street, Fort Bandra Kurla Complex Mumbai - 400 001 Bandra (E) Mumbai - 400 051 Scrip Code: 543271 Trading Symbol: JUBLINGREA Sub: Investors Presentation Dear Sirs, In terms of Regulation
Slide 2: Jubilant Ingrevia Limited Investor Presentation October 2024
Jubilant Ingrevia Limited Investor Presentation October 2024 1
Slide 3: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 4: Chairmen’s Message on Q2’FY25 Financial Results | 1/2
Chairmen’s Message on Q2’FY25 Financial Results | 1/2 “We are pleased to announce a healthy QoQ & YoY growth for the quarter, fueled by the enhanced performance of our Speciality Chemicals and Nutrition & Health Solutions Businesses, as well as the advantages gained from cost-saving measures impleme
Slide 5: Chairmen’s Message on Q2’FY25 Financial Results | 2/2
Chairmen’s Message on Q2’FY25 Financial Results | 2/2 In the Chemical Intermediates Business, QoQ growth was attributed to an increase in volumes of Ethyl Acetate and Acetic Anhydride. However, the YoY performance declined mainly due to lower prices. Agrochemical CDMO Update: We are excited to share
Slide 6: Table of Contents
Table of Contents 0 6 Company Overview 1 1 Growth Roadmap 1 5 Q2’FY25 Highlights 2 2 Business Segments Update 5
Slide 7: Company Overview
Company Overview Our Lighthouse Site Visuals 6 6
Slide 8: Jubilant Ingrevia is the oldest and third largest company in Jubilant Bhartia Group
Jubilant Ingrevia is the oldest and third largest company in Jubilant Bhartia Group 45+ years 2300+ people 3rd largest of legacy in Chemicals space, started with strong leadership team with Company in the Jubilant Group average 25+ years of experience in in 1978 as VAM Organic Chemicals Chemicals sp
Slide 9: Our business is split across 3 business verticals
Our business is split across 3 business verticals, with global leadership across our key product lines 41% Revenue Mix 17% Revenue Mix 41% Revenue Mix 57% EBITDA Mix # 16% EBITDA Mix # 27% EBITDA Mix # Specialty Chemicals Nutrition & Health Solutions Chemical Intermediates CDMO (Pharma, Agro, Semi
Slide 10: We serve customers across geographies and sectors
We serve customers across geographies and sectors; increased growth from exports and pharma/cosmetic/nutrition sectors in recent years Our Product Platforms Enable us to serve diverse customer segments and market needs 1• Pyridine Geographical Revenue Split End-use Industry Revenue Split 2• Diketene
Slide 11: Executive Leadership Team
Executive Leadership Team Deepak Jain (43 yrs) Chandan Singh (60 yrs) CEO & MD Advisor Relatively new, young, energized & 20 years of industry & 37 years of industry experienced leadership team Consulting experience experience Business Leaders Function Leaders Specialty Chemicals Nutrition & Health
Slide 12: Growth Roadmap (Recap)
Growth Roadmap (Recap)
Slide 13: Our new ‘Compass’ forms the bedrock of our future growth roadmap
Our new ‘Compass’ forms the bedrock of our future growth roadmap PURPOSE VISION Enable a Sustainable World through Leading provider of innovative solutions Chemistry in our core chemistries globally Customer Centricity World-class, Safe Innovation & ESG Leader People Focused Operations Technology Cu
Slide 14: Recap: Future Growth Aspiration to grow 3x in next years – PINNACLE 3.4.5
Recap: Future Growth Aspiration to grow 3x in next 5 years PINNACLE 3.4.5 13
Slide 15: Last one year: progress in our Pinnacle 345 journey
Last one year: We have already started to make good progress in our Pinnacle 345 journey Creation of a tight budget with 120 Turnaround in Cr+ of Lean/Surge/BE initiatives Specialty and CDMO contract Major events / milestones Nutrition with with Agro Commissioning of DKT plants increase in Innovator
Slide 16: Q2 & H1’FY25 Highlights
Q2 & H1’FY25 Highlights 15 15
Slide 17: Market Overview: Q2 & H1’FY25
Market Overview: Q2 & H1’FY25 | Gradual recovery in volumes across segments; prices are still soft in most segments PHARMA • Steady demand with good visibility on volumes across segments; volume growth seen in Pyridine derivatives • Stability in prices across segments; uptick in some areas • Paracet
Slide 18: Key business highlights Q2FY25
Key business highlights Q2FY25: Significant growth in our core categories, higher margins on account of product mix & cost initiatives • Pyridine & Picoline: Significant volume growth on YoY basis; world’s largest and only non- Core product platforms continue to Chinese scaled player in Pyridine dri
Slide 19: Financial Results Overview | Q2 & H1’FY25 Consolidated
Financial Results Overview | Q2 & H1’FY25 Consolidated 1 Particulars Q2'FY24 Q1'FY25 Q2'FY25 Q-o-Q Y-o-Y H1'FY24 H1'FY25 Y-o-Y Total Revenue 1,020 1,024 1,045 2.0% 2.5% 2,095 2,070 -1.2% Total EBITDA 126 119 135 13.4% 7.0% 251 254 1.1% EBITDA Margin (%) 12% 12% 13% 12% 12% Profit After Tax 57 49 59
Slide 20: We are seeing a gradual recovery from the lows of H2’FY24
We are seeing a gradual recovery from the lows of H2’FY24 EBITDA (INR Crs.) EBITDA Margins 135 125 126 119 12.9% 11.6% 12.1% 11.6% 10.8% 9.4% 104 101 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Revenue 1075 1020 966 1074 1024 1045 (INR Crs) 19
Slide 21: Secular YoY and QoQ EBITDA growth across Specialty Chemicals and Nutrition
We continue to see secular YoY and QoQ EBITDA growth across Specialty Chemicals and Nutrition along with margin expansion Specialty Chemicals Nutrition & Health Solutions EBITDA (Rs Cr.) EBITDA (Rs Cr.) Y.o.Y Growth 26% Y.o.Y Growth 29% Q.o.Q Growth 1% Q.o.Q Growth 5% 86 87 24 23 69 19 18% 20% 20% 5
Slide 22: WEF recognises Bharuch facility as a Global Manufacturing Lighthouse
WEF recognises Bharuch facility as a Global Manufacturing Lighthouse Jubilant Ingrevia is now a member of the elite Global Lighthouse Network (GLN) of the World Economic Forum (WEF) Global Lighthouse Network Digital Impact @ Bharuch GLN is a community of 172 Bharuch manufacturing site is designated
Slide 23: Business Segments Overview
Business Segments Overview 22
Slide 24: Specialty Chemicals | Market, Business & Financial Highlights
1 Specialty Chemicals | Market, Business & Financial Highlights MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS Steady demand from the end-use segment, volumes remain strong; pricing remained Particulars 1 Q2'FY24 Q1'FY25 Q2'FY25 Q-o-Q Y-o-Y H1'FY24 H1'FY25 Y-o-Y steady with uptick in select segments Pharma
Slide 25: Nutrition & Health Solutions | Market, Business & Financial Highlights
2 Nutrition & Health Solutions | Market, Business & Financial Highlights MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS Witnessed improved Niacinamide pricing on 1 QoQ basis Particulars Q2'FY24 Q1'FY25 Q2'FY25 Q-o-Q Y-o-Y H1'FY24 H1'FY25 Y-o-Y Increased sales volume and gained market Segment Revenue 162 186
Slide 26: Chemical Intermediates | Market, Business & Financial Highlights
3 Chemical Intermediates | Market, Business & Financial Highlights MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS The primary end-use markets for Paracetamol 1 continued to face challenges Particulars Q2'FY24 Q1'FY25 Q2'FY25 Q-o-Q Y-o-Y H1'FY24 H1'FY25 Y-o-Y Modest recovery was observed in the Segment Reven
Slide 27: Annexures
Annexures 26 26
Slide 28: Annexure I - Income Statement | Consolidated – Q2 & H1‘FY25
Annexure I - Income Statement | Consolidated – Q2 & H1‘FY25 Particulars1 Q2'FY24 Q1'FY25 Q2'FY25 QoQ YoY H1'FY24 H1'FY25 YoY Revenue from operations a) Sales/Income from operations 1011 1010 1029 2% 2% 2080 2039 -2% b) Other operating income 9 14 16 17% 84% 15 30 98% Total revenue from operations 10
Slide 29: Annexure II: Income Statement Segmental – Q2 & H1’FY25
Annexure II: Income Statement Segmental – Q2 & H1’FY25 Particulars1 Q2'FY24 Q1'FY25 Q2'FY25 QoQ (%) YoY (%) H1'FY24 H1'FY25 YoY (%) Total Revenue from Operations 1,020 1,024 1,045 2% 2% 2,095 2,070 (1%) Speciality Chemicals 382 431 433 1% 13% 745 864 16% Nutrition & Health Solutions 162 186 182 (2%)
Slide 30: Annexure III: Debt Position | As on 30th September 2024
Annexure III: Debt Position| As on 30th September 2024 1 Particulars 30-Sep-23 30-Jun-24 30-Sep-24 Long Term Borrowings 300 450 450 Short Term Borrowings 457 291 263 Total Gross Debt 757 741 713 Cash & Equivalent 56 64 63 Total Net Debt 701 677 650 YoY change -7% • The capex for the quarter was Rs 9
Slide 31: Annexure III - Conference Call Details
Annexure III - Conference Call Details Diamond Pass Log-In Date : October 22nd, 2024 Time : 05:00 pm IST To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. Pre-registration: You will receive dial in numbers, p
Slide 32: Thank you for your time
For More Information For Investors: Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pavleen Taneja Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customised products and solutions Jubilant Ingrevia Limi
Slide 33: Jubilant Ingrevia Limited – Q2 & H1 FY25 Results (Press Release)
Jubilant Ingrevia Limited 1A, Sector 16A, Noida – 201301, India Tel.: +91 120 4361000 PRESS RELEASE www.jubilantingrevia.com Noida, Tuesday, October 22nd, 2024 JUBILANT INGREVIA LIMITED – Q2 & H1 FY25 RESULTS 1 Particulars Q2'FY24 Q1'FY25 Q2'FY25 Q-o-Q Y-o-Y H1'FY24 H1'FY25 Y-o-Y Total Revenue 1,020
Slide 34: Q2’FY25 Highlights | Segment Wise Analysis A. Speciality Chemicals
Agrochemical CDMO Update: We are excited to share that we have signed a five-year agreement with a multinational Agro-innovator to produce a key intermediate for one of their strategic agrochemicals. Jubilant Ingrevia limited will manufacture this intermediate using the MNC's proprietary technology.
Slide 35: B. Nutrition & Health Solutions
Business Highlights - CDMO business remains on the growth trajectory, signed USD 300 Million+, 5-year CDMO contract with an MNC Agro Innovator - Witnessed increase in volumes of high-margin Fine Chemicals Pyridine derivatives both QoQ and YoY - The Di-ketene plant operated at a healthy utilization l
Slide 36: C. Chemical Intermediates Segment
Financial Highlights - Revenue for the quarter improved YoY on account of higher volumes from sale of both animal and human grade Niacinamide with higher pricing - Improvement in EBITDA on QoQ and YoY basis due to: Higher prices of Niacinamide Favorable shift in volume mix towards human-grade pr
Slide 37: Income Statement and Segment P&L – Q2’FY25
3. Income Statement – Q2’FY25 Particulars1 Q2'FY24 Q1'FY25 Q2'FY25 QoQ YoY H1'FY24 H1'FY25 YoY Revenue from operations a) Sales/Income from operations 1011 1010 1029 2% 2% 2080 2039 -2% b) Other operating income 9 14 16 17% 84% 15 30 98% Total revenue from operations 1020 1024 1045 2% 2% 2095 2070 -
Slide 38: Debt Position as on 30th September, 2024
5. Debt Position as on 30th September, 2024 1 Particulars 30-Sep-23 30-Jun-24 30-Sep-24 Long Term Borrowings 300 450 450 Short Term Borrowings 457 291 263 Total Gross Debt 757 741 713 Cash & Equivalent 56 64 63 Total Net Debt 701 677 650 YoY change -7% All figures are in Rs Crore unless otherwise st
Slide 39: For more information, please contact
For more information, please contact: For Investors Pavleen Taneja Siddharth Rangnekar Jubilant Ingrevia Limited CDR India Ph: +91-120 436 1000 Ph: +91 22 6645 1209 E-mail: siddharth@cdr-india.com E-mail: pavleen.taneja@jubl.com For Media Sandipan Ghatak Ph: +91-120 436 1062 E-mail: sandipan.ghatak@